%0 Journal Article
%T Podium Session 1: Prostate Cancer June 26, 2016 1050¨C1150
%J Archive of "Canadian Urological Association Journal".
%D 2016
%X The phase 2 TERRAIN trial compared the efficacy and safety of enzalutamide (ENZA) vs. bicalutamide (BIC) in patients (pts) with metastatic castration-resistant prostate cancer who had progressed on luteinizing hormone-releasing hormone agonist/antagonist therapy or after bilateral orchiectomy while maintaining castration therapy during the study. An age effect analysis was pre-specified to investigate the efficacy and safety of ENZA vs. BIC. Results are presented in younger (<75 years) and older (¡Ý75 years) pts in the TERRAIN population
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413364/